XRAY Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

924.64M

+2.17%

0.287

+10.5%

898.84M

+2.26%

0.388

-9.77%

938.32M

+0.25%

0.466

-10.44%

Estimates Revision

The market is revising Downward the revenue expectations for DENTSPLY SIRONA Inc. (XRAY) for FY2025, with the revenue forecasts being adjusted by -0.26% over the past three months. During the same period, the stock price has changed by 4.58%.

Revenue Estimates for FY2025

Revise Downward

-0.26%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-13.37%

In Past 3 Month

Stock Price

Go Up

+4.58%

In Past 3 Month

15 Analyst Rating

Wall Street analysts forecast XRAY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XRAY is 13.42 USD with a low forecast of 12.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

13 Hold

0 Sell

Hold

Current: 0.000

Low

12.00

Averages

13.42

High

17.00

Current: 0.000

Low

12.00

Averages

13.42

High

17.00

Baird

Neutral

downgrade

$14 -> $12

2025-12-16

Reason

Baird

Price Target

$14 -> $12

2025-12-16

downgrade

Neutral

Reason

Baird lowered the firm's price target on Dentsply Sirona to $12 from $14 and keeps a Neutral rating on the shares. The firm adjusted ratings and price targets in medical technology as part of its 2026 outlook. Baird sees "several potential paths to improved" share performance for the group in 2026.

Barclays

Underweight

initiated

$12

2025-12-08

Reason

Barclays

Price Target

$12

2025-12-08

initiated

Underweight

Reason

Barclays initiated coverage of Dentsply Sirona with an Underweight rating and $12 price target. The firm started the U.S healthcare technology and distribution industry with a neutral view. Barclays is most bullish on the drug distributors and has a more mixed view of the dental and healthcare information technology sub-sectors.

Barrington

Michael Petusky

Outperform

downgrade

$18 -> $14

2025-11-10

Reason

Barrington

Michael Petusky

Price Target

$18 -> $14

2025-11-10

downgrade

Outperform

Reason

Barrington analyst Michael Petusky lowered the firm's price target on Dentsply Sirona to $14 from $18 and keeps an Outperform rating on the shares. While stating that Dentsply Sirona has "turned into the ultimate 'prove it" story," the firm believes the current valuation reflects "maximum skepticism" and argues that the risk/reward continues to favor investors with patience.

Piper Sandler

Neutral

downgrade

$16 -> $13

2025-11-07

Reason

Piper Sandler

Price Target

$16 -> $13

2025-11-07

downgrade

Neutral

Reason

Piper Sandler lowered the firm's price target on Dentsply Sirona to $13 from $16 and keeps a Neutral rating on the shares. The firm notes the company reported Q3 results, with revenue finishing just ahead of Street but EBITDA and EPS missed. Guidance was cut across the board, and while in part a formality with investors already anticipating such a move, challenges in the U.S. are larger than originally thought, Piper adds.

Baird

Neutral

downgrade

$18 -> $14

2025-11-07

Reason

Baird

Price Target

$18 -> $14

2025-11-07

downgrade

Neutral

Reason

Baird lowered the firm's price target on Dentsply Sirona to $14 from $18 and keeps a Neutral rating on the shares. The firm updated its model following Q3 results which provided many updates by low visibility remains.

JPMorgan

Neutral

downgrade

$14 -> $12

2025-11-07

Reason

JPMorgan

Price Target

$14 -> $12

2025-11-07

downgrade

Neutral

Reason

JPMorgan lowered the firm's price target on Dentsply Sirona to $12 from $14 and keeps a Neutral rating on the shares.

Valuation Metrics

The current forward P/E ratio for DENTSPLY SIRONA Inc (XRAY.O) is 7.33, compared to its 5-year average forward P/E of 15.90. For a more detailed relative valuation and DCF analysis to assess DENTSPLY SIRONA Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

15.90

Current PE

7.33

Overvalued PE

21.19

Undervalued PE

10.61

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

11.85

Current EV/EBITDA

7.01

Overvalued EV/EBITDA

14.88

Undervalued EV/EBITDA

8.82

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

1.88

Current PS

0.61

Overvalued PS

2.69

Undervalued PS

1.08

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

XRAY News & Events

Events Timeline

No data

News

1.0

01-06Globenewswire

Dentsply Sirona to Present at 44th Annual J.P. Morgan Healthcare Conference

6.0

2025-12-16Benzinga

Accenture Set to Surge Over 16%? Check Out 10 Leading Analyst Predictions for Tuesday

8.0

2025-12-01NASDAQ.COM

DENTSPLY SIRONA Recognized as Leading Dividend Stock with Insider Purchases and 5.64% Yield (XRAY)

People Also Watch

Frequently Asked Questions

What is DENTSPLY SIRONA Inc (XRAY) stock price today?

The current price of XRAY is 12.78 USD — it has increased 2.4 % in the last trading day.

What is DENTSPLY SIRONA Inc (XRAY)'s business?

DENTSPLY SIRONA Inc. is a manufacturer of professional dental products and technologies. It develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices. Its Connected Technology Solutions segment includes design, manufacture and sales of its dental technology and equipment products. Its Essential Dental Solutions segment includes the development, manufacture and sales of its value-added endodontic, restorative, and preventive consumable products and small equipment used by dental professionals for the treatment of patients. Its Orthodontic and Implant Solutions segment includes the design, manufacture, and sales of its various digital implant systems and dental implant products, digital dentures and dental professional-directed aligner solutions. Its Wellspect Healthcare segment includes the design, manufacture, and sales of its continence care solutions for urinary and bowel management.

What is the price predicton of XRAY Stock?

What is DENTSPLY SIRONA Inc (XRAY)'s revenue for the last quarter?

DENTSPLY SIRONA Inc revenue for the last quarter amounts to 904.00M USD, decreased -4.94 % YoY.

What is DENTSPLY SIRONA Inc (XRAY)'s earnings per share (EPS) for the last quarter?

DENTSPLY SIRONA Inc. EPS for the last quarter amounts to -2.14 USD, decreased -13.01 % YoY.

What changes have occurred in the market's expectations for DENTSPLY SIRONA Inc (XRAY)'s fundamentals?

How many employees does DENTSPLY SIRONA Inc (XRAY). have?

DENTSPLY SIRONA Inc (XRAY) has 14000 emplpoyees as of January 10 2026.

What is DENTSPLY SIRONA Inc (XRAY) market cap?

Today XRAY has the market capitalization of 2.55B USD.